AgelessRx Review

What AgelessRx charges

• Sermorelin: $149/mo — per month after the first; the first month is $99 on a three-month plan billed in full
• NAD+: $149/mo — per month after the first; the first month is $79 on a three-month plan billed in full
• PT-141: $199/mo — per month ongoing; the first month is $149
• GHK-Cu: $99/mo — for the 0.5% cream; the same page prints this figure once as a first-month rate and once as an ongoing one
• Glutathione: $99/mo — starting rate on the three-month plan; the plain monthly rate is not published on that page

Start with the price, because the headline is not the price

Every peptide on this site is advertised as starting at a figure. On three of the five product pages, the ongoing rate appears a paragraph or two below, and it is considerably higher.

The sermorelin page advertises a starting figure and then states that it applies to the first month on a three-month plan billed in full, with a higher rate afterward. The NAD+ page follows the same pattern.

The PT-141 page is the most explicit of the three. It prints the introductory figure, the discount it represents, and the ongoing monthly rate on the same line.

The rows on this site carry the ongoing figure wherever the page publishes one, with the introductory rate named in the qualifier. Taking the headline instead would understate every one of them.

The GHK-Cu page disagrees with itself

The cream is offered in two strengths. The hero section prints a figure for each and labels both as first-month rates.

Further down, a strength comparison prints the same two figures as plain monthly rates. A third block describes a discount off the first month, which implies a higher ongoing rate again.

Three readings of one price sit on one page. The row here takes the published figure and says in the qualifier that the page prints it both ways, because picking one and staying quiet would hide the thing a buyer needs to know.

What it has decided not to sell

The peptide page names BPC-157, TB-500, MOTS-c and KPV in a section describing compounds under evaluation rather than on sale. It offers a notification list instead of a product.

A seller publishing what it has turned down is unusual. It is also the reason those four compounds carry no AgelessRx figure anywhere on this site, and that absence is the company's own stated position rather than a gap in what was read.

The glutathione page is a partial case. It advertises a starting rate and says the figure applies to the three-month plan, without publishing what the plain monthly plan costs.

Formats, terms and one claim to discount

Sermorelin and PT-141 are each sold as an injection and as a nasal spray, priced separately. The nasal option costs more than the injection for sermorelin and the same for PT-141.

The product pages say a plan can be paused or canceled at any time, and that dispensing runs through licensed United States compounding pharmacies. None of those pharmacies is named.

The site repeatedly cites a placing in a longevity research competition. That is a marketing claim about the company, not an independent assessment of the products it sells, and it should not be read as one.

No state coverage list is published on the pages read here, so coverage cannot be checked before an assessment.

How we verified this

• Read the peptide category page and the sermorelin, NAD+, PT-141, GHK-Cu and glutathione product pages, and recorded the figure printed on each.
• Recorded the ongoing rate separately from the introductory rate on every page that published both, and used the ongoing figure for the price rows here.
• Recorded that the GHK-Cu page prints the same figure as a first-month rate in one section and as a monthly rate in another.
• Read the section of the peptide page listing BPC-157, TB-500, MOTS-c and KPV as compounds under evaluation rather than on sale.
• Confirmed from the terms of service that the pages read are operated by AgelessRx, and found no state coverage list on them.
• Requested a nonsense path on the same host in the same session; it returned a not-found response of a different size from the pages read.